According to reports from Business Standard, Beta Drugs reported a consolidated net profit of ₹9.05 crore for the quarter ended March 2026, representing a 0.22% increase from ₹9.03 crore in the corresponding quarter of the previous year. The company's sales revenue rose marginally by 0.21% to ₹93.96 crore compared to ₹93.76 crore in Q4 FY2025. The quarterly performance showed mixed results with operational metrics remaining relatively stable.
As reported by Business Standard, for the full financial year ended March 2026, Beta Drugs net profit declined by 2.22% to ₹41.48 crore from ₹42.42 crore in the previous year. However, the company demonstrated stronger revenue growth with sales increasing by 6.20% to ₹384.83 crore compared to ₹362.36 crore in FY2025. The annual performance showed contrasting trends between profitability and revenue expansion.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) for Q4 FY2026 stood at 18.82% compared to 18.50% in the same quarter of the previous year. For the full year, the OPM declined to 19.67% from 20.59% in FY2025. The PBDT (Profit Before Depreciation and Tax) for Q4 was ₹16.63 crore against ₹18.02 crore in Q4 FY2025, while PBT (Profit Before Tax) decreased to ₹11.83 crore from ₹14.45 crore year-on-year.
